Efficacy and safety of camrelizumab combined with FOLFOX as neoadjuvant therapy for patients with resectable locally advanced gastric and gastroesophageal junction adenocarcinoma who received D2 radical gastrectomy.

Yuzhou Zhao(Capital Medical University), Xijie Zhang(Zhengzhou University), Jinbang Wang(Dalian National Laboratory for Clean Energy), Chen-Yu Liu(Institute on Governance), Guangsen Han(Zhengzhou University), Gangcheng Wang(Zhengzhou University), Sen Li(Xi'an Jiaotong University), Pengfei Ma(First Affiliated Hospital of Zhengzhou University), Junli Zhang(Target (United States)), Yanhui Gu(Zhengzhou University), Zhimeng Li(Zhengzhou University), Jing Zhuang(Zhengzhou University), Yanghui Cao(Zhengzhou University), Baodong Li(Zhengzhou University)
Journal of Clinical Oncology
May 20, 2020
Cited by 2


Related Papers